Daily Anesthesiology Research Analysis
Analyzed 101 papers and selected 3 impactful papers.
Summary
Three impactful studies span mechanistic sepsis immunology, resolution-phase analgesia, and neuroprognostication. A Cell Death and Differentiation paper uncovers an EGFR–MAPK14–CEBPβ–PGLYRP1–TREM1 circuit driving neutrophil NETosis in sepsis, revealing therapeutic targets. A JCI study shows Protectin DX (a specialized proresolving mediator) relieves postoperative pain via GPR37 and macrophage efferocytosis while modulating nociceptors; and a Critical Care Medicine meta-analysis finds glial fibrillary acidic protein (GFAP) offers time-dependent prognostic accuracy after cardiac arrest.
Research Themes
- Neutrophil NETosis signaling and sepsis immunopathology
- Specialized proresolving mediators for perioperative analgesia
- Time-dependent biomarkers for neuroprognostication after cardiac arrest
Selected Articles
1. EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction.
This mechanistic study identifies EGFR as a neutrophil-intrinsic driver of NETosis in sepsis via an EGFR–MAPK14–CEBPβ–PGLYRP1–TREM1 axis. Neutrophil-specific EGFR deletion improves survival and reduces cytokine storm and NETs; rescue with recombinant PGLYRP1 confirms pathway centrality.
Impact: Reveals a druggable signaling circuit linking EGFR to pathological NETosis, offering concrete targets (EGFR, MAPK14, PGLYRP1/TREM-1) to mitigate neutrophil-driven organ injury in sepsis.
Clinical Implications: Supports exploration of EGFR or TREM-1/PGLYRP1–axis inhibitors as adjuncts in severe sepsis to reduce NETosis and immunopathology; may refine patient stratification using neutrophil EGFR expression.
Key Findings
- EGFR is upregulated in neutrophils from sepsis patients and correlates with disease severity.
- Neutrophil-specific EGFR knockout improves survival and reduces cytokine storm, tissue injury, and NET formation in polymicrobial sepsis.
- EGFR recruits MAPK14 to phosphorylate CEBPβ, driving PGLYRP1 transcription; PGLYRP1 amplifies NETosis via autocrine TREM-1 signaling.
- Recombinant PGLYRP1 or CEBPβ overexpression reverses the protective effects of EGFR deletion, confirming pathway centrality.
Methodological Strengths
- Human–mouse translational approach with patient neutrophil data and conditional neutrophil-specific EGFR deletion.
- Mechanistic dissection with protein–protein interactions, kinase recruitment, transcriptional activation, and phenotypic rescue experiments.
Limitations
- Preclinical mouse models may not fully recapitulate human sepsis heterogeneity.
- Potential off-target or immunosuppressive effects of EGFR/MAPK14 pathway inhibition require careful evaluation.
Future Directions: Test pharmacologic EGFR, MAPK14, or TREM-1/PGLYRP1 inhibitors in sepsis models with comorbidities; validate neutrophil EGFR/CEBPβ/PGLYRP1 signatures as biomarkers; design early-phase clinical trials targeting this axis.
Excessive neutrophil activation and NET release drive systemic inflammation and organ injury in sepsis, yet the upstream regulatory pathways remain incompletely defined. Here, we identify epidermal growth factor receptor (EGFR) as a critical neutrophil-intrinsic regulator of NETosis. EGFR expression was markedly elevated in neutrophils from patients with sepsis and correlated with disease severity. Neutrophil-specific EGFR deletion in mice improved survival after polymicrobial sepsis by reducing cytokine storm, tissue injury, and NET formation. Mechanistically, EGFR associated with CCAAT/enhancer-binding protein beta (CEBPβ) and recruited Mitogen-activated protein kinase 14 (MAPK14) to phosphorylate CEBPβ, promoting its nuclear localization and transcriptional activation of peptidoglycan recognition protein 1 (PGLYRP1). Elevated PGLYRP1, in turn, amplified NETs release via autocrine engagement of triggering receptor expressed on myeloid cell-1 (TREM-1), establishing a feed-forward inflammatory loop. Administration of recombinant PGLYRP1 or forced CEBPβ overexpression reversed the protection conferred by EGFR deficiency, confirming the centrality of this axis. These findings define an unrecognized EGFR-MAPK14-CEBPβ-PGLYRP1-TREM1 circuit that links receptor signaling to pathological NETosis and highlight a promising therapeutic target to attenuate neutrophil-driven immunopathology in sepsis.
2. Protectin DX resolves fracture-induced postoperative pain in mice via neuronal signaling and GPR37-activated macrophage efferocytosis.
Protectin DX provided superior and resolution-promoting analgesia in a fracture-induced postoperative pain model, dependent on GPR37. It enhanced macrophage efferocytosis via calcium signaling and rapidly dampened nociceptor activity, outperforming PD1/DHA, steroids, and meloxicam and shortening pain duration.
Impact: Introduces a proresolving analgesic mechanism that reduces pain duration rather than merely suppressing pain, highlighting GPR37 as a translational target for perioperative analgesia.
Clinical Implications: Supports development of specialized proresolving mediator–based analgesics to control postoperative pain while avoiding steroid/NSAID-related drawbacks (e.g., delayed resolution). Suggests patient stratification by GPR37 pathways in future trials.
Key Findings
- IV Protectin DX (100 ng/mouse) alleviates early and late phases of fracture-induced postoperative pain and shortens pain duration.
- PDX outperformed PD1/DHA, steroids, and meloxicam; dexamethasone and meloxicam prolonged pain, whereas PDX shortened it.
- Analgesic effects require GPR37: absent in Gpr37−/− mice; PDX binds GPR37 and induces macrophage calcium responses and efferocytosis.
- PDX rapidly suppresses nociceptor activity (C-fiber reflex, DRG calcium responses) and reduces TRPA1/TRPV1-induced acute pain/inflammation.
Methodological Strengths
- Head-to-head comparison with PD1/DHA, steroids, and meloxicam; both early and late treatment windows tested.
- Genetic validation (Gpr37−/−), receptor binding and functional assays, lipidomics, and multi-system readouts (macrophages and neurons).
Limitations
- Preclinical mouse data; human pharmacokinetics, dosing, and safety are unknown.
- Mechanism centered on GPR37 may not generalize across pain etiologies or species.
Future Directions: Evaluate PDX analogs with improved pharmacokinetics; test GPR37 pathway engagement and biomarkers in large animal models; conduct phase I safety and PK studies followed by efficacy trials in high-pain surgeries.
Protectin DX (PDX) is a member of the superfamily of specialized proresolving mediators and exerts anti-inflammatory actions in animal models; however, its signaling mechanism remains unclear. Here, we demonstrate the analgesic actions of PDX in a mouse model of tibial fracture-induced postoperative pain (fPOP). Intravenous early- and late-phase treatment of PDX (100 ng/mouse) effectively alleviated fPOP. Compared with protectin D1 (PD1)/neuroprotectin D1, DHA, steroids, and meloxicam, PDX provided superior pain relief. While dexamethasone and meloxicam prolonged fPOP, PDX shortened the pain duration. The analgesic effects of PDX were abrogated in Gpr37-/- mice, which displayed deficits in fPOP resolution. PDX was shown to bind GPR37 and induce calcium responses in peritoneal macrophages. LC-MS/MS-based lipidomic analysis revealed that endogenous PDX levels were approximately 10-fold higher than those of PD1 in muscle at the fracture site. PDX promoted macrophage polarization via GPR37-dependent phagocytosis and efferocytosis through calcium signaling in vitro, and it further enhanced macrophage viability and efferocytosis in vivo via GPR37. Finally, PDX rapidly modulated nociceptor neuron responses by suppressing C-fiber-induced muscle reflex in vivo and calcium responses in DRG neurons ex vivo and by reducing TRPA1/TRPV1-induced acute pain and neurogenic inflammation in vivo. Our findings highlight multiple benefits of PDX to manage postoperative pain and promote perioperative recovery.
3. Neuroprognostication After Cardiac Arrest Using Glial Fibrillary Acidic Protein: A Systematic Review and Meta-Analysis.
GFAP predicts poor neurologic outcomes after cardiac arrest with improving discrimination at later timepoints, peaking at 48–72 h post-ROSC (AUC up to 0.88). Findings support incorporating GFAP into multimodal prognostication, with caveats about heterogeneity and need for standardized cutoffs.
Impact: Provides quantitative, time-resolved evidence supporting GFAP as a neuroprognostic biomarker, informing when to sample and how to integrate into multimodal algorithms.
Clinical Implications: Measure GFAP at 48–72 h post-ROSC alongside EEG, imaging, and clinical exam to improve prognostic accuracy and avoid premature withdrawal of life-sustaining therapy.
Key Findings
- GFAP levels are significantly higher in patients with poor neurologic outcomes at 24, 48, and 72 h post-ROSC.
- Prognostic accuracy improves over time with pooled AUCs of 0.76 (24 h), 0.84 (48 h), and 0.88 (72 h).
- Subgroup analyses (6-month outcomes, out-of-hospital arrest) show consistent results; moderate risk of bias in selection and timing noted.
Methodological Strengths
- Systematic, multi-database search with QUADAS-2 assessment and timepoint-specific meta-analyses.
- Subgroup analyses enhance external validity (e.g., 6-month outcomes, out-of-hospital cardiac arrest).
Limitations
- Heterogeneity in assays, sample matrices, and thresholds; moderate risk of bias in patient selection and flow/timing.
- Predominantly observational underlying studies; causality cannot be inferred.
Future Directions: Prospective, standardized GFAP measurement protocols with predefined cutoffs; integrate GFAP with multimodal prognostic models and assess clinical impact on decision-making and outcomes.
OBJECTIVES: To evaluate the prognostic accuracy of glial fibrillary acidic protein (GFAP) levels in predicting poor neurologic outcomes in adult patients after cardiac arrest, across different post-resuscitation timepoints. DATA SOURCES: PubMed, Scopus, Web of Science, and Google Scholar were systematically searched up to June 12, 2025. STUDY SELECTION: Eligible studies included randomized controlled or observational studies enrolling adult or pediatric patients with in- or out-of-hospital cardiac arrest who achieved return of spontaneous circulation (ROSC), measured GFAP in any biofluid, and reported neurologic outcomes. DATA EXTRACTION: Three independent reviewers extracted data on study design, population, arrest characteristics, GFAP sampling methods, outcome definitions, and prognostic performance. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. DATA SYNTHESIS: Twenty studies were included in the systematic review; 12 contributed to meta-analyses. Median GFAP levels were significantly higher in patients with poor neurologic outcomes at 24 hours (Δ = 138.1 pg/mL), 48 hours (Δ = 471.1 pg/mL), and 72 hours (Δ = 745.7 pg/mL) post-ROSC. Summary area under the curve values for prognostic accuracy improved over time: 0.76 at 24 hours, 0.84 at 48 hours, and 0.88 at 72 hours. Subgroup analyses limited to 6-month outcomes and out-of-hospital arrests showed consistent results. Quality assessment revealed low applicability concerns but moderate risk of bias in patient selection and flow/timing. CONCLUSIONS: GFAP demonstrates time-dependent prognostic utility in predicting poor neurologic outcomes after cardiac arrest in adults, with optimal performance at 48-72 hours post-ROSC. These findings support suggest that GFAP shows potential as a time-dependent biomarker but remains investigational. Further prospective studies are needed to validate its clinical utility and to determine standardized cutoff values before routine implementation.